Discussion  by unknown
numbers of elderly patients with more comorbidities un-
dergo valve replacement, the influence of valve-related fac-
tors on mortality rate is likely to continue to decline com-
pared with patient-related factors. In addition, with the
improved durability of later generation tissue valves, the
long-term results of mechanical valve replacement are also
likely to be affected by increased use of bioprosthetic valves
in younger patients.
In summary, this series of patients undergoing AVR and
MVR with the St Jude Medical mechanical prosthesis with
follow-up to 20 years confirms the excellent performance of
this valve that we have documented in our earlier reports. In
addition, the complete absence of structural valve deterio-
ration makes the St Jude Medical mechanical heart valve
prosthesis an excellent choice for patients who require me-
chanical prosthetic valve replacement.
References
1. Crawford FA Jr, Kratz JM, Sade RM, Stroud MR, Bartles DM. Aortic
and mitral valve replacement with the St Jude Medical prosthesis. Ann
Surg. 1984;199:753-61.
2. Kratz JM, Crawford FA Jr, Sade RM, Crumbley AJ III, Stroud MR. St
Jude prosthesis for aortic and mitral valve replacement: a ten year
experience. Ann Thorac Surg. 1993;56:462-8.
3. Arom KV, Nicoloff DM, Kersten TE, Lindsay WG, Northrup WF III.
St Jude Medical prosthesis: valve-related deaths and complications.
Ann Thorac Surg. 1987;43:591-8.
4. Arom KV, Nicoloff DM, Kersten TE, Northrup WF III, Lindsay WG,
Emery RW. Ten years’ experience with the St Jude Medical valve
prosthesis. Ann Thorac Surg. 1989;47:831-7.
5. Czer LS, Chaux A, Matloff JM, et al. Ten-year experience with the St
Jude Medical valve for primary valve replacement. J Thorac Cardio-
vasc Surg. 1990;100:44-55.
6. Khan S, Chaux A, Matloff J, et al. The St Jude Medical valve.
Experience with 1000 cases. J Thorac Cardiovasc Surg. 1994;108:
1010-20.
7. Zellner JL, Kratz JM, Crumbley AJ III, et al. Long-term experience
with the St Jude Medical valve prosthesis. Ann Thorac Surg. 1999;68:
1210-8.
8. Remadi JP, Baron O, Roussel C, et al. Isolated mitral valve replace-
ment with St Jude Medical prosthesis: long-term results: a follow-up of
19 years. Circulation. 2001;103:1542-5.
9. Lund O, Nielsen SL, Arildsen H, Ilkjaer LB, Pilegaard HK. Standard
aortic St Jude valve at 18 years: performance profile and determinants
of outcome. Ann Thorac Surg. 2000;69:1459-65.
10. Emery RW, Arom KB, Kshettry VR, et al. Decision-making in the
choice of heart valve for replacement in patients aged 60-70 years:
twenty-year follow up of the St Jude Medical aortic valve prosthesis.
J Heart Valve Dis. 2002;11(Suppl 1):S37-44.
11. Edmunds LH, Clark RE, Cohn LH, Miller DC, Weisel RD. Guidelines
for reporting morbidity and mortality after cardiac valvular operations.
Ann Thorac Surg. 1996;62:932-5.
12. Grunkemeier GL, Lambert LE, Bonchek LI, Starr A. An improved
statistical method for assessing the results of an operation. Ann Thorac
Surg. 1975;20:289-98.
13. Bodnar E, Wain WH, Haberman S. Assessment and comparison of the
performance of cardiac valves. Ann Thorac Surg. 1982;34:146-56.
14. Kaplan EL, Meier P. Non-parametric estimation from incomplete
observations. J Am Stat Assoc. 1958;53:457-81.
15. Grunkenmeier GL, Starr A. The expected lifetime of porcine valves.
Ann Thorac Surg. 1989;48:317-8.
16. Hosmer DW, Lemeshow S. Applied logistic regression. New York:
Wiley; 2000.
17. Cox DR, Oakes D. Analysis of survival data. London: Chapman and
Hall; 1984.
18. Emery RW, Nicoloff DM. St Jude Medical cardiac valve prosthesis: in
vitro studies. J Thorac Cardiovasc Surg. 1979;78:269-76.
19. Gray RJ, Chaux A, Matloff JM, et al. Bileaflet, tilting disc and porcine
valve substitutes: in vivo hydrodynamic characteristics. J Am Coll
Cardiol. 1984;3:321-7.
20. Khan SS, Trento A, DeRobertis M, et al. Twenty-year comparison of
tissue and mechanical valve replacement. J Thorac Cardiovasc Surg.
2001;122:257-69.
21. Masters RG, Helou J, Pipe AL, Keon WJ. Comparative clinical out-
comes with St Jude Medical, Medtronic Hall and CarboMedics me-
chanical heart valves. J Heart Valve Dis. 2001;10:403-9.
22. Butchart EG, Li HH, Payne N, Buchan K, Grunkemeier GL. Twenty
years’ experience with the Medtronic Hall valve. J Thorac Cardiovasc
Surg. 2001;121:1090-100.
23. Anttila V, Heikkinen J, Biancari F, et al. A retrospective comparative
study of aortic valve replacement with St Jude medical and Medtronic-
Hall prostheses: a 20-year follow-up study. Scand Cardiovasc J.
2002;36:53-9.
24. Ibrahim SA. Hypertension and medication adherence among African
Americans: a potential factor in cardiovascular disparities. J Natl Med
Assoc. 2003;95:28-9.
25. Khurana C, Rosenbaum CG, Howard BV, et al. Coronary artery
calcification in black and white women. Am Heart J. 2003;145:724-9.
26. Adeniyi A, Folsom AR, Brancati FL, Desvorieux M, Pnakow JS,
Taylor H. Incidence and risk factors for cardiovascular disease in
African Americans with diabetes: the Atherosclerosis Risk in Com-
munities (ARIC) study. J Natl Med Assoc. 2002;94:1025-35.
27. Arom KV, Emery RW, Nicoloff DM, Petersen RJ. Anticoagulant
related complications in elderly patients with St Jude mechanical valve
prostheses. J Heart Valve Dis. 1996;5:505-10.
28. Horstkotte D, Schulte HD, Bircks W, Strauer BE. Lower intensity
anticoagulation therapy results in lower complication rates with the St
Jude Medical prosthesis. J Thorac Cardiovasc Surg. 1994;107:1136-
45.
29. Tozzi P, Al-Darweesh A, Vogt P, Stumpe F. Silver-coated prosthetic
heart valve: a double-bladed weapon. Eur J Cardiothorac Surg. 2001;
19:729-31.
30. Sepelt RG, Vazquez-Jimenez JF, Seipelt IM, et al. The St Jude
“Silzone” valve: midterm results in treatment of active endocarditis.
Ann Thorac Surg. 2001;72:758-62.
31. Herijgers P, Herregods MC, Vandeplas A, Meyns B, Flameng W.
Silzone coating and paravalvular leak: an independent, randomized
study. J Heart Valve Dis. 2001;10:712-5.
32. Rosner B. Fundamentals of biostatistics. 5th ed. Belmont: Duxbury
Press; 2000.
33. Arias E, Smith BL. Deaths: Preliminary Data for 2001. National vital
statistics reports. Hyattsville, Maryland: National Center for Health
Statistics. 2003;51(5).
Discussion
Dr Alfredo Trento (Los Angeles, Calif). This is an important
retrospective review because it further conclusively supports with
a longer follow-up the data on the St Jude Medical valve, which I
think can be translated with minor differences to the other bileaflet
valves.
Two years ago we published our 20-year comparison between
St Jude Medical and tissue valves. There were 670 St Jude Medical
valves and 720 tissue valves in the aortic position, about 500 St
Jude Medical valves and 400 tissue valves in the mitral position.
The mean age of patients with the St Jude Medical valve was
almost 10 years greater. The 10- and 20-year actuarial survival for
all the patients with mechanical and biological prostheses was
similar to that presented here by you today.
Freedom from thromboembolic events was also similar for both
St Jude Medical and tissue valves in both aortic and mitral posi-
tion. Freedom from hemorrhage was also similar. The only differ-
ence is that in the aortic position, biological prostheses fared much
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better, with a freedom from hemorrhage of 94% and 92% at 10 and
20 years, respectively.
We have also learned from other retrospective studies, as well
from the 2 randomized studies that are published, that in general,
long-term survival is not influenced by the type of valve that we
use, mechanical or biologic, but by other factors, as you men-
tioned, like age, coronary artery disease, New York Heart Asso-
ciation class, diabetes, and finally, and probably, valve to patient
size mismatch.
In view of this background, justifiably or not, over the past 10
years, in the aortic position we have reduced the use of St Jude
Medical valves from 55% in 1991 to less than 20% in 2002. In the
mitral position the same things happened in favor of mitral valve
repair.
Quality of life, freedom from warfarin, and increased mobility
of the patient population, which makes follow-up more difficult,
have steered patients and physicians away from warfarin. Has your
experience been similar on the choice of valves? Could you also
relate the thromboembolic and hemorrhagic complications to the
patient’s INR when they happen? Was the patient’s INR out of
range?
Now, the most important issue is the warfarin therapy. How
low do you think you can push the INR? Do you think we can have
a safe anticoagulation for the aortic valve with an INR between 1.5
and 2 for the aortic position and an INR around 2 for the mitral
position? That would make warfarin therapy much more attractive.
Dr Ikonomidis (Charleston, SC). Thank you, Dr Trento, for
those insightful comments and questions. With regard to compar-
ing mechanical valves to tissue valves, what we have observed is
what has generally been observed in most studies, namely that the
durability of mechanical valves exceeds that of tissue valves,
whereas tissue valves show superior freedom from thromboem-
bolic and bleeding complications.
As far as relating thromboembolic and hemorrhagic complica-
tions to the patient’s INR, we didn’t specifically relate the inci-
dence of the complication to the INR, but that would be something
that worth looking at. As far as decreasing the targeted INR is
concerned, despite the fact that we have decreased the INR in our
institution, this has not resulted in an increase in thromboembolic
rates; in fact, it has still dropped to a small extent. Therefore, at the
present time we feel that our current target INRs are safe.
Dr Kit V. Arom (Minneapolis, Minn). I rise to congratulate the
group from Charleston for their excellent long-term follow-ups,
particularly with 98% completed. We, too, in Minneapolis, after
Demetre Nicoloff implanted the first valve in 1977, have followed
these people up to 20 years. At that time with 95.4% complete
(21,342 patient years), we had 3937 patients available for the
study. About 1300 of the patients were dead at that time or
approximately one third of them.
The causes of death were 4.5% valve-related, 4% related to
anticoagulation. The rest of them died from ongoing atherosclero-
sis and heart failure (48%). Linearized rate (percent per patient-
year) included 1.24 for thromboembolism (TE), 1.00 for bleeding,
0.1 for perivalvular leak, 0.18 for prosthetic endocarditis, and
valve thrombosis was 0.09.
If we translate this into actuarial analysis, we obtained results
similar to yours, except in 2 areas. One is that at the end of 20
years our aortic valve had better survival rate than the mitral valve,
being about 44%, comparing with about 33% for the mitral valve.
And the other area was the incidence free from bleeding and
TE. There was about 82% incidence free from bleeding and 70%
free from TE. If I remember correctly, this is quite different than
yours, which it is about 60%.
We did lower the intensity of anticoagulation in 1985 by
keeping the INR between 1.8 and 2.5 for AVR, 2.5 and 3.2 for
MVR.
Dr Trento has suggested lowering intensity of anticoagulation,
which I agree with. At the present time we still using a slightly
lower intensity than what you just described, and I think this could
be the reason why we see a slightly better TE and bleeding rate.
Dr Ikonomidis. How did you conduct the follow-up on your
patients?
Dr Arom. Our follow-up is not quite as good as yours, which
is being done yearly. We hope, however, that we can use the same
approach that you do. In 1985, we also instructed the cardiologist
and family physician to stop using prothrombin values and to have
the INR strictly within the range that I have mentioned. I really
believe that this approach has contributed to our recent outcomes.
Dr Ikonomidis. The less aggressive warfarin dosing that you
described may help address your improved freedom from TE and
bleeding compared with our series. In addition, conducting fol-
low-up over longer time intervals may cause patients to forget
some events, effectively increasing the documented freedom from
TE and bleeding complications.
As for addressing the flip in terms of aortic and mitral valve
survival, I think that this discrepancy may reflect inherent differ-
Appendix. Variables examined for association with
operative mortality and late death
Operative mortality Late survival
Aortic valves Aortic valves
Gender Gender
Age at operation Age at operation
Body surface area Year of surgery
Year of surgery Race
Race Valve size  21 mm
Valve size 19 mm Effective orifice area 2.59
CABG 3 or more vessels Effective orifice area index
Reoperation Associated CABG
Preoperative NYHA class IV Reoperation
Lesion (aortic stenosis) Preoperative NYHA class III or IV
Lesion (aortic stenosis)
Mitral valves Mitral valves
Gender Gender
Age at operation Age at operation
Body surface area Year of surgery
Year of surgery Race
Race Valve size
Valve size 19 mm Associated CABG
CABG 3 or more vessels Reoperation
Reoperation Preoperative NYHA class III or IV
Preoperative NYHA class IV Lesion (mitral insufficiency)
Lesion (mitral insufficiency) Ischemic etiology
Ischemic etiology
NYHA, New York Heart Association; CABG, coronary artery bypass graft-
ing.
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ences in the population as they relate to severity of comorbid
factors such as hypertension, left ventricular hypertrophy, and
perhaps even compliance with medications.
Dr W. R. Eric Jamieson (Vancouver, British Columbia, Can-
ada). Congratulations on an excellent study. I just have 2 short
questions. You shared with us your linearized occurrence rates for
aortic and mitral valves. Could you share with us the linearized
rates for major embolisms, including Reversible Ischemic Neuro-
logic Deficits, and comment also on early and late events, because
many patient mechanical populations can have major events in the
first 30 days.
My second question is related: have you looked at actual versus
actuarial freedoms when you assess the composites of complica-
tions, morbidity, mortality, and reoperation, which are probably
better parameters when you are counseling patients to have a
mechanical or any prosthesis?
Dr Ikonomidis. I am sorry, Dr Jamieson, can you repeat the
second question?
Dr Jamieson. The concept of using actual freedoms compared
with actuarial freedoms, which are better parameters to use when
counseling patients as to which prosthesis they should have.
Dr Ikonomidis. All of the nondeath outcomes were analyzed
by cumulative incidence analysis. I did not include them here in
this presentation for purposes of simplicity but in all end points
measured, the cumulative incidence curves were all shifted upward
compared with the actuarial freedom curves, as one would expect.
With regard to neurologic events, approximately one third were
early and then the remaining two thirds occurred later on.
Dr Mohammed A. Quader (Cleveland, Ohio). Congratula-
tions on your excellent presentation of this valuable data. I would
like to ask you a question about the use of 19-mm valves. Fifteen
percent of the patients had the 19-mm valve placed, and multivar-
iate analysis has shown that there is an increased risk of death with
that. Has there been a trend toward not using this valve more
frequently in the recent past?
Also, have you looked for patient-prosthesis mismatch in that
group of patients?
Dr Ikonomidis. We have trended toward not using 19-mm
valves as much as possible. As far as patient-prosthesis mismatch
is concerned, neither EOA nor EOA index were found to be
multivariate predictors of death.
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